

DAFTAR PUSTAKA

1. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. *Nat Rev Dis Primers*. 2021;7(1).
2. Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. *Clin Chem Lab Med*. 2020;58(3):326–39.
3. David MK, Leslie SW. Prostate Specific Antigen. *NCBI Bookshelf*. 2022;1–6.
4. Moradi A, Srinivasan S, Clements J, Barra J. Beyond the biomarker role. prostate-specific antigen (PSA) in the prostate cancer microenvironment. *Cancer and Metastasis Reviews*. 2019;38(3):333–46.
5. Leslie SW, Soon-Sutton TL, Sajjad H, Siref. LE. Prostate Cancer. *StatPearls*. 2022;
6. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. *Cold Spring Harb Perspect Med*. 2018;8(12).
7. Matsushita M, Fujita K, Nonomura N. Influence of diet and nutrition. *Int J Med Sci*. 2020;21:1–18.
8. Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017. *MMWR Morb Mortal Wkly Rep*. 2020;69(41):1473–80.
9. Nordström T, Akre O, Aly M, Grönberg H, Eklund M. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. *Prostate Cancer Prostatic Dis*. 2018;21(1):57–63.
10. Gandaglia G, Albers P, Abrahamsson PA, Briganti A, Catto JWF, Chapple CR, et al. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. *Eur Urol*. 2019;76(2):142–50.
11. Kanani S, Mujtaba N, Sadler P. Acute and chronic prostatitis. *InnovAiT: Education and inspiration for general practice*. 2021;14(1):33–7.




12. Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. *Biomedicine and Pharmacotherapy*. 2017;94:1064–76.
13. Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. *Nat Rev Urol*. 2018;15(1):11–24.
14. Karakose A, Yuksel MB, Pirincci N, Gorgel SN, Atesci YZ, Gumus B. The effect of antibiotherapy on high serum PSA levels. *Eastern Journal of Medicine*. 2015;20(1):30–3.
15. H KM, Mehta NH, Babu M, Bansal D, Mehta S, Pillai BS, et al. Can Antibiotic Therapy avoid Unnecessary Biopsy in Males with Marginally Elevated PSA Levels ? 2017;X(2):66–70.
16. Taha DE, Aboumarzouk OM, Koraiem IO, Shokeir AA. Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review. *Arab J Urol*. 2020;18(1):1–8.
17. Ittmann M. *Anatomy and Histology of the Human and Murine Prostate*. Cold Spring Harb Perspect Med. 2018;8(5):1–6.
18. Nehikhare O, Kasivisvanathan V, Ellis H, Challacombe B. Anatomy, physiology and pathology of the large prostate. *The Big Prostate*. 2017;1–10.
19. Pérez-ibave DC, Burciaga-flores CH. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. 2018;54(March):48–55.
20. Putra IBOW, Hamid ARAH, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. *Prostate Int*. 2016;4(2):43–8.
21. MacKintosh FR, Sprenkle PC, Walter LC, Rawson L, Karnes RJ, Morrell CH, et al. Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer. *Front Oncol*. 2016;6(JUN):1–7.



22. AlDhaheri HN, AlSaimary IE, ALMusafer MM. prostatitis by fully automated ELISA technique . Journal of Medical Research and Health Sciences. 2020;3(11):1100–3.
23. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
24. Saeed Alqahtani W, Abdulrahman Almufareh N, Mostafa Domiaty D, Albasher G, Abdulllah Alduwish M, Alkhalaf H, et al. Epidemiology of cancer in Saudi Arabia thru 2010–2019: a systematic review with constrained meta-analysis Running title: epidemiology of cancer in Saudi Arabia thru 2010–2019. AIMS Public Health. 2020;7(3):679–96.
25. Kweon SS. Updates on Cancer Epidemiology in Korea, 2018. Chonnam Med J. 2018;54:90–100.
26. Monoarfa A, Tjandra F. Profil penderita kanker prostat di RSUP Prof . Dr . R . D . Kandou Manado. e-Clinic. 2016;4(2):1–8.
27. Folkmanis K, Junk E, Merdane E, Folkmane I, Folkmanis V, Isajevs S. Current Trends in Prostate Cancer Etiology, Pathogenesis and Diagnostics. Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences. 2021;75(5):319–27.
28. Malik SS, Batool R, Masood N, Yasmin A. Risk factors for prostate cancer: A multifactorial case-control study. Curr Probl Cancer. 2018;42(3):337–43.
29. Tse LA, Ho WM, Wang F, He YH, Ng CF. Environmental risk factors of prostate cancer: a case-control study. Hong Kong Med J. 2018;24(4):30–3.
30. Benedito E, Brito N De, Weller M. Risk factors of prostate cancer: a case-control study in Northeast Brazil Fatores. Saud Pesq. 2022;15(1):1–12.
31. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis. 2005;26(7):1170–81.



32. Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. *Cancer Med.* 2019;8(3):1110–23.
33. Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, et al. Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: Detection using prostatectomy and needle biopsy specimens. *Cells.* 2019;8(3):1–11.
34. Russo GI, Calogero AE, Condorelli RA, Scalia G, Morgia G, La Vignera S. Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis. *Aging Male.* 2020;23(2):132–8.
35. Descotes JL. Diagnosis of prostate cancer. *Asian J Urol.* 2019;6(2):129–36.
36. Tikkinen KAO, Dahm P, Lytvyn L, Heen AF, Vernooij RWM, Siemieniuk RAC, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: A clinical practice guideline. *BMJ (Online).* 2018;362.
37. Ali AJ, Thaker Thiab. Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4–10 ng/ml). *Al-Anbar Medical Journal.* 2020;16(2):31–4.
38. Rabani S, Mousavizadeh A. The Effect of Ofloxacin in Men With Elevated Prostate Specific Antigen. 2021;1–10.
39. Busato WFS, Almeida GL, Geraldo J, Busato FS. Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL? *International Braz J Urol.* 2015;41(2):329–36.
40. Atalay HA, Canat L, Alkan İ, Çakir SS, Altunrende F. Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study. *Prostate Int.* 2017;5(2):59–64.
41. Greiman A, Shah J, Bhavsar R, Armeson K, Caulder S, Jones R, et al. Six Weeks of Fluoroquinolone Antibiotic Therapy for Patients With Elevated Serum Prostate-specific



Antigen Is Not Clinically Beneficial: A Randomized Controlled Clinical Trial. *Urology*. 2016;90(2016):32–8.

42. Durrani AS, Rahim J, Afzal U, Rana AUR, Rahim J, Shaukat Z. Role of antibiotics in reduction of raised serum PSA levels and avoidance of unnecessary prostatic biopsies. *Pakistan Journal of Medical and Health Sciences*. 2020;14(4):1238–40.

43. Serretta V, Catanese A, Daricello G, Liotta R, Allegro R, Martorana A, et al. PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. *Prostate Cancer Prostatic Dis*. 2008 Jun;11(2):148–52.

44. Karakose A, Bilgehan Yuksel M, Pirincci N, Gorgel SN, Atesci YZ, Gumus B. The effect of antibiotherapy on high serum PSA levels. Vol. 20, *Eastern Journal of Medicine*. 2015.

45. Putra IBOW, Hamid ARAH, Mochtar CA, Umbas R. Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. *Prostate Int*. 2016 Jun 1;4(2):43–8.

46. American Cancer Society. Key Statistics for Prostate Cancer [Internet]. [cited 2022 Oct 15]. Available from: <https://www.cancer.org>

47. Buddingh KT, Maatje MGF, Putter H, Kropman RF, Pelger RCM. Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. *Canadian Urological Association Journal*. 2018 Jan 1;12(1):E25–30.

48. Rajakumari SN, Arasi K v, Anandan H. Serum Prostate-specific Antigen Following Antibiotics in Symptomatic Patients with Lower Urinary Tract Symptoms [Internet]. Vol. 32, *International Journal of Scientific Study*. 2019. Available from: www.ijss-sn.com

49. Özman O, Talat Z. New Parameters in Evaluation of PSA Decrease after Antibiotherapy; PSA half-life and PSA-ENT. *International Archives of Urology and Complications*. 2019 Jun 30;5(1).



50. Toktas G, Demiray M, Erkan E, Kocaaslan R, Yucetas U, Unluer SE. The effect of antibiotherapy on prostate-specific antigen levels and prostate biopsy results in patients with levels 2.5 to 10 ng/mL. *J Endourol.* 2013 Aug 1;27(8):1061–7.
51. al Jalham K, Younes N, Badawi A, Khalafalla K, Majzoub A. Antibiotics for elevated prostate specific antigen: Where do we stand? *Urol Sci.* 2016 Sep 1;27(3):154–7.
52. Fandella A, Benvenuto S, Guidoni E, Giampaoli M, Bertaccini A. Empiric antibiotics therapy for mildly elevated prostate specific antigen. Helpful to avoid unnecessary biopsies? *Archivio Italiano di Urologia e Andrologia.* 2014;86(3):202–4.

